Past, present and future uses of methacholine testing

Methacholine challenge testing is a valuable diagnostic and research tool used by clinicians to assist in the diagnosis of asthma, and by researchers to understand disease pathophysiology and assess novel therapeutic efficacy. The use of methacholine challenge in asthma relates to its direct effect on airway smooth muscle (i.e., bronchoconstriction) as a measure of airway hyperresponsiveness, a cardinal feature of asthma. Airway hyperresponsiveness has been documented in other airway disorders, including chronic obstructive pulmonary disease, cystic fibrosis and allergic rhinitis; however, there is little clinical application of methacholine challenge in these conditions as a diagnostic or disease management tool. The authors will review the aspects of methacholine challenge testing, as they relate to asthma, and point out its usefulness in clinical research. A brief review of past (historical) uses and speculation as to the future uses of methacholine challenge will also be discussed.

[1]  C. Jackson,et al.  A randomized primary care trial of steroid titration against mannitol in persistent asthma: STAMINA trial. , 2012, Chest.

[2]  C. Lemière,et al.  Comparison of methacholine and mannitol bronchial provocation tests in workers with occupational asthma. , 2012, The Journal of allergy and clinical immunology.

[3]  A. McIvor,et al.  Update on exhaled nitric oxide in pulmonary disease , 2012, Expert review of respiratory medicine.

[4]  K. Killian,et al.  Dose–response effects of TPI ASM8 in asthmatics after allergen , 2011, Allergy.

[5]  G. Ciprandi,et al.  Relationship between bronchial hyperreactivity and bronchodilation in patients with allergic rhinitis. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  M. Dolhnikoff,et al.  Cholinergic Hyperresponsiveness of Peripheral Lung Parenchyma in Chronic Obstructive Pulmonary Disease , 2011, Respiration.

[7]  L. Boulet,et al.  Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. , 2011, American journal of respiratory and critical care medicine.

[8]  D. Jarvis,et al.  Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. , 2011, American journal of respiratory and critical care medicine.

[9]  M. Chan-yeung,et al.  Airway hyperresponsiveness to methacholine in 7‐year‐old children: sensitivity and specificity for pediatric allergist‐diagnosed asthma , 2011, Pediatric Pulmonology.

[10]  J. Fahy,et al.  Negative methacholine challenge tests in subjects who report physician‐diagnosed asthma , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  C. Porsbjerg,et al.  Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: a random-sample population study. , 2010, The Journal of allergy and clinical immunology.

[12]  C. Roussos,et al.  Pulmonary function tests, sputum induction, and bronchial provocation tests: diagnostic tools in the challenge of distinguishing asthma and COPD phenotypes in clinical practice , 2010, International journal of chronic obstructive pulmonary disease.

[13]  F. Hargreave,et al.  Airway Hyperresponsiveness in Asthma: Its Measurement and Clinical SignificanceMeasuring Bronchitis in Airway Diseases: Clinical Implementation and Application: Airway Hyperresponsiveness in Asthma: Its Measurement and Clinical Significance , 2010 .

[14]  J. Brannan Bronchial hyperresponsiveness in the assessment of asthma control: Airway hyperresponsiveness in asthma: its measurement and clinical significance. , 2010, Chest.

[15]  S. Anderson,et al.  Indirect Challenge Tests Airway Hyperresponsiveness in Asthma : Its Measurement and Clinical Signifi cance , 2010 .

[16]  L. Boulet,et al.  Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma. , 2009, The Journal of allergy and clinical immunology.

[17]  C. Porsbjerg,et al.  Diagnostic properties of inhaled mannitol in the diagnosis of asthma: a population study. , 2009, The Journal of allergy and clinical immunology.

[18]  L. Boulet,et al.  Single-dose desloratadine and montelukast and allergen-induced late airway responses , 2009, European Respiratory Journal.

[19]  L. Boulet,et al.  Comparative airway response to high- versus low-molecular weight agents in occupational asthma , 2009, European Respiratory Journal.

[20]  P. Calverley,et al.  Lung function changes following methacholine inhalation in COPD. , 2009, Respiratory medicine.

[21]  S. Anderson,et al.  Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma , 2009, Respiratory research.

[22]  L. Williams,et al.  Two ATS Recommended Protocols for Administration of Methacholine Are Not Equal , 2009, The Journal of asthma : official journal of the Association for the Care of Asthma.

[23]  T. Ahmed,et al.  The effect of IVX‐0142, a heparin‐derived hypersulfated disaccharide, on the allergic airway responses in asthma , 2008, Allergy.

[24]  L. Boulet,et al.  Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. , 2008, American journal of respiratory and critical care medicine.

[25]  A. Kozyrskyj,et al.  Diagnosing asthma in children: What is the role for methacholine bronchoprovocation testing? , 2008, Pediatric pulmonology.

[26]  S. Anderson,et al.  Relationship between airway responsiveness to mannitol and to methacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  S. Anderson,et al.  Monitoring asthma therapy using indirect bronchial provocation tests * , 2007, The clinical respiratory journal.

[28]  Y. Jiong,et al.  Persistent airway inflammation and bronchial hyperresponsiveness in patients with totally controlled asthma , 2007, International journal of clinical practice.

[29]  I. Pavord,et al.  The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. , 2007, American journal of respiratory and critical care medicine.

[30]  D. Cockcroft,et al.  Mechanisms of airway hyperresponsiveness. , 2006, The Journal of allergy and clinical immunology.

[31]  L. Prieto,et al.  Effect of challenge method on sensitivity, reactivity, and maximal response to methacholine. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[32]  D. Cockcroft,et al.  The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result. , 2006, The Journal of allergy and clinical immunology.

[33]  D. Cockcroft,et al.  Difference between dosimeter and tidal breathing methacholine challenge: contributions of dose and deep inspiration bronchoprotection. , 2005, Chest.

[34]  J. Cowan,et al.  Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. , 2005, The New England journal of medicine.

[35]  S. Anderson,et al.  Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept. , 2005, Pulmonary pharmacology & therapeutics.

[36]  D. Cockcroft,et al.  Methacholine challenge: comparison of two methods. , 2005, Chest.

[37]  D. Cockcroft,et al.  Dosimeter methacholine challenge: comparison of maximal versus submaximal inhalations. , 2004, The Journal of allergy and clinical immunology.

[38]  Jan Stolk,et al.  Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[39]  D. Postma,et al.  Direct or indirect stimuli for bronchial challenge testing: what is the relevance for asthma epidemiology? , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  S. Anderson,et al.  Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma. , 2003, Chest.

[41]  L. Corbetta,et al.  Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[42]  S. Holgate,et al.  Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. , 2002, The Journal of allergy and clinical immunology.

[43]  P. O'Byrne,et al.  Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. , 2002, American journal of respiratory and critical care medicine.

[44]  C. Jenkins,et al.  Markers of airway inflammation and airway hyperresponsiveness in patients with well-controlled asthma. , 2001, European Respiratory Journal.

[45]  D. Cockcroft,et al.  Tolerance to the bronchoprotective effect of beta2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. , 1999, The Journal of allergy and clinical immunology.

[46]  J. Vandenbroucke,et al.  Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. , 1999, American journal of respiratory and critical care medicine.

[47]  Boulet,et al.  Directives de la Societe canadienne de thoracologie pour l'asthme professionnel canadian thoracic society guidelines for occupational asthma , 1998, Canadian respiratory journal.

[48]  D. Yates,et al.  Effect of an inhaled glucocorticosteroid on mast cell and smooth muscle beta 2 adrenergic tolerance in mild asthma. , 1998, Thorax.

[49]  M. W. Jensen,et al.  Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. , 1997, American journal of respiratory and critical care medicine.

[50]  D. Cockcroft,et al.  Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. , 1997, Thorax.

[51]  A. Zwinderman,et al.  Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma. , 1997, The Journal of allergy and clinical immunology.

[52]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[53]  S. Durham,et al.  A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[54]  D. Jarvis,et al.  The European Community Respiratory Health Survey II , 1994, European Respiratory Journal.

[55]  D. Cockcroft,et al.  Regular inhaled salbutamol and airway responsiveness to allergen , 1993, The Lancet.

[56]  P. Barnes,et al.  Tolerance to the Nonbronchodilator Effects of Inhaled β2-Agonists in Asthma , 1992 .

[57]  S. Holgate,et al.  The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. , 1989, The American review of respiratory disease.

[58]  F. Speizer,et al.  The relationship of nonspecific bronchial responsiveness to respiratory symptoms in a random population sample. , 1987, The American review of respiratory disease.

[59]  D. Cockcroft,et al.  Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. , 1987, The Journal of allergy and clinical immunology.

[60]  M. Yamakido,et al.  Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma. , 2009, Allergology international : official journal of the Japanese Society of Allergology.

[61]  S. Willsie Allergic Rhinitis and Onset of Bronchial Hyperresponsiveness: A Population-based Study , 2009 .

[62]  L. Boulet,et al.  Adult Asthma Consensus Guidelines update 2003. , 2004, Canadian respiratory journal.

[63]  J. Hankinson,et al.  Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. , 2000, American journal of respiratory and critical care medicine.

[64]  L. Boulet,et al.  Canadian Thoracic Society guidelines for occupational asthma. , 1998, Canadian respiratory journal.

[65]  J. Connett,et al.  Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. , 1996, American journal of respiratory and critical care medicine.

[66]  P. Barnes,et al.  Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. , 1992, The New England journal of medicine.

[67]  A. Zwinderman,et al.  The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. , 1991, The American review of respiratory disease.